Mexdagry

Metformin Hydrochloride and Dapagliflozin, the active ingredients in Mexdagry, are a Biguanide and SGLT2 inhibitor combination presented as a tablet for oral use. This fixed‑dose product lowers blood glucose by improving insulin sensitivity and increasing urinary glucose excretion, and is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Mexdagry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable global distribution.

Mexdagry, a combination of metformin and dapagliflozin, is used to improve glycemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves blood glucose levels as part of diet and exercise regimen. - Inadequate control on metformin alone: provides additional HbA1c reduction when added to existing metformin therapy. - Combination with other antidiabetic agents: enhances overall glucose management alongside sulfonylureas, insulin or GLP‑1 receptor agonists.

Common and serious adverse reactions have been reported with the Metformin/Dapagliflozin combination.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools that may improve over time. - Genital mycotic infection: itching or discharge, especially in women.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Ketoacidosis: euglycemic diabetic ketoacidosis may develop. - Acute kidney injury: sudden decline in renal function.

When prescribing Mexdagry, several precautions should be observed to ensure patient safety. - Renal function assessment: evaluate eGFR before initiation and periodically thereafter. - Hepatic impairment risk: avoid in patients with significant liver disease due to lactic acidosis potential. - Hydration status: maintain adequate fluid intake to reduce risk of dehydration and renal events. - Risk of genital infections: monitor for symptoms and advise proper hygiene. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at room temperature: keep in original container, protect from moisture and heat.

Mexdagry may interact with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute kidney injury when combined with metformin. - Insulin or sulfonylureas: increase risk of hypoglycemia. - Cimetidine: may raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Diuretics: may enhance dehydration and affect blood pressure. - Alcohol: can increase risk of lactic acidosis.